CHMP: label extension for GSK's Cervarix; recommendation for Behring’s IgG
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's human papillomavirus vaccine, Cervarix is poised to win a line extension for preventing premalignant genital lesions, including vulvar and vaginal lesions. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) gave the extension the green light at this month's meeting.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.